Advertisement

PharmacoEconomics

, Volume 37, Issue 12, pp 1553–1553 | Cite as

Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review

  • Dongzhe Hong
  • Lei Si
  • Minghuan Jiang
  • Hui Shao
  • Wai-kit Ming
  • Yingnan Zhao
  • Yan Li
  • Lizheng ShiEmail author
Correction

1 Correction to: PharmacoEconomics (2019) 37:777–818  https://doi.org/10.1007/s40273-019-00774-9

The term “CORE diabetes model” was used throughout the article for consistency. However, there is variation in referencing the original “CORE diabetes model” in the literature [1]: among a total of 37 relevant cost-effectiveness analysis studies published from 2007 to 1 June 2018, 13 studies referenced the model as the “CORE Diabetes Model”, 21 as the “IMS CORE Diabetes Model”, two as the “QuintilesIMS Health CORE Diabetes Model”, and one as the “IQVIA CORE Diabetes Model”. The existence in the literature of multiple names for this model is due to company mergers. For clarification, since 2017 this model has officially been called the “IQVIA CORE Diabetes Model”.

Reference

  1. 1.
    Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20(Suppl 1):S5–26.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Dongzhe Hong
    • 1
  • Lei Si
    • 2
  • Minghuan Jiang
    • 3
    • 4
  • Hui Shao
    • 1
  • Wai-kit Ming
    • 5
    • 6
  • Yingnan Zhao
    • 7
  • Yan Li
    • 8
    • 9
  • Lizheng Shi
    • 1
    Email author
  1. 1.Department of Health Policy and Management, School of Public Health and Tropical MedicineTulane UniversityNew OrleansUSA
  2. 2.The George Institute for Global HealthUniversity of New South WalesKensingtonAustralia
  3. 3.The Department of Pharmacy Administration and Clinical Pharmacy, School of PharmacyXi’an Jiaotong UniversityXi’anChina
  4. 4.The Center for Drug Safety and Policy ResearchXi’an Jiaotong UniversityXi’anChina
  5. 5.The First Affiliated HospitalSun Yat-sen UniversityGuangzhouChina
  6. 6.Harvard Medical SchoolBostonUnited States
  7. 7.College of PharmacyXavier University of LouisianaNew OrleansUSA
  8. 8.The New York Academy of MedicineNew YorkUSA
  9. 9.Department of Population Health Science and PolicyIcahn School of Medicine at Mount SinaiNew YorkUSA

Personalised recommendations